Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK

Jozaa Z. ALTamimi, Ghdeir M. Alshammari, Nora A. AlFarisa, Reham I. Alagaly, Dalal H. Aljabry, Norah A. Albekairi, Mahmoud Ahmad Alkhateeb and Mohammed Abdo Yahya

Nutrition and Food Science, Department of Physical Sport Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia;
Department of Food Science and Nutrition, College of Food and Agricultural Sciences, King Saud University, Riyadh, Saudi Arabia;
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;
Department of Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia

ABSTRACT
Context: Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia.
Objective: This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats.
Materials and methods: Adult male Wistar rats (130 ± 10 g) were divided into 6 groups (n = 8 rats/group) as control, control + EA, control + EA + CC an AMPK inhibitor). T1DM, T1DM + EA, and T1DM + EA + CC. The treatments with EA (50 mg/kg/orally) and CC (200 ng/rat/i.p.) were given the desired groups for 12 weeks, daily.
Results: In T1DM-rats, EA reduced fasting glucose levels (44.8%), increased fasting insulin levels (92.8%), prevented hepatic lipid accumulation, and decreased hepatic and serum levels of total triglycerides (54% & 61%), cholesterol (57% & 48%), and free fatty acids (40% & 37%). It also reduced hepatic levels of ROS and inflammation; oxidative stress; oxidative stress; lipid metabolism.
Discussion and conclusions: These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further in vivo and in vitro studies are needed to validate its potential in clinical medicine.

Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide that results from excessive lipid retention in the liver and encompasses a wide spectrum of hepatic conditions ranging from simple fatty liver to non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma (Bhatt and Smith 2015). NAFLD is a risk factor for the development of renal, cardiovascular, and cerebrovascular disorders (Hazelehurst et al. 2016). The available data indicate that the global prevalence of NAFLD is about 25% (Younossi et al. 2016). In 2014, the prevalence estimates of NAFLD in men was 10.8% versus 14.9% in women, numbers that are projected to increase to reach 21% in women and 18% in men by 2025 (Araújo et al. 2018).

Although NAFLD is mainly common in individuals with obesity, type 2 DM (T2DM), and metabolic syndrome (Met S), NAFLD is also common in patients with T1DM (Hazelehurst et al. 2016; Mohamed et al. 2016; Sviklánová et al. 2018; Tripolino et al. 2019; de Vries et al. 2020). Therefore, early detection and management of NAFLD in T1DM is crucial to prevent hepatic damage and other health co-morbidities.

Yet, the pathogenesis of mechanisms of NAFLD in T1DM is still unclear. Available experimental suggest that hepatic oxidative stress due to increased production of reactive oxygen species (ROS) and concomitant reduction in antioxidants in response to an increasing influx of glucose and free fatty acids (FFAs) is the major mechanism responsible for hepatic inflammation, ischemia/reperfusion (I/R), fibrosis, necrosis, and apoptosis (Ucar et al. 2013; Mohamed et al. 2016; Kitade et al. 2017; Masarone et al. 2018). Besides, independent of oxidative stress, T1DM is associated with several independent pathological mechanisms that stimulate hepatic lipid synthesis- and lipogenesis. These include impaired VLDL-c secretion, increased glucose uptake and conversion to fats, abnormally upregulated transcription factors including the carbohydrate-responsive element-binding protein (ChREBP), and the sterol regulatory element-binding protein 1 (SREBP1c) (Bhatt and Smith 2015).

The current investigation was undertaken to provide a better understanding of the pathogenesis of NAFLD in T1DM and T2DM. In this context, the role of the 5‘AMP-activated protein kinase (AMPK), an important cellular energy sensor, in the process of hepatic steatosis and NAFLD has become increasingly of interest to many researchers around the world (Smith et al. 2016). AMPK is a key signalling molecule that plays a crucial role in regulating hepatic lipid metabolism. Indeed, AMPK inhibits FFAs, triglycerides (TGs), and cholesterol (CHOL) synthesis by downregulating...
SREBP1 and SREBP2 transcription factors, respectively (Tomita et al. 2005; Yang et al. 2009; Knebel et al. 2012; Quan et al. 2013; Tang et al. 2016; de Souza et al. 2017; Ren et al. 2019). It also stimulates the mitochondria fatty acids (FAs) by activating/upregulating the peroxisome proliferator-activated receptor-alpha transcription factor (P帕ARα) (de Souza et al. 2017; Ren et al. 2019). Of interest, the hepatic levels and activities of AMPK are significantly depleted in animal models of NAFLD, including those induced by high-fat diet (HFD) and T2DM (Fogarty and Hardie 2010; Kulkarni et al. 2013; Lindholm et al. 2013; Smith et al. 2016; Liou et al. 2019). However, the pharmacological activation of AMPK in these animal models ameliorated hepatic damage and steatosis (Smith et al. 2016; Liou et al. 2019). Despite these findings, the impact of T1DM on the hepatic expression of AMPK concerning NAFLD was not well investigated and poorly described in the literature and needs further investigation.

Ellagic acid is a polyphenol abundant in various fruits, including strawberries, pomegranate, guava, walnuts, almonds, and green tea in the form of hydrolyzable tannins called ellagitannins (Evtuyugin et al. 2020). In the intestine, ellagitannins are metabolized to EA, which is metabolized into more absorbable metabolites called urolithin, which may mediate its pharmacological effects (Evtyugin et al. 2020). In the intestine, ellagitannins are metabolized to EA, which is metabolized into more absorbable metabolites called urolithin, which may mediate its pharmacological effects (Djedjibegovic et al. 2020). At the clinical and experimental levels, EA possessed several pharmacological health benefits, including acting as an anticancerogenic, antiviral, anti-inflammatory, antibacterial, antimalarial, antidiabetic, antianxiety, and antiatherogenic molecule (Goswami et al. 2014; Ayhanc et al. 2016; Seo et al. 2016; Polce et al. 2018; Aslan et al. 2020). EA is a potent hepatoprotective, nephroprotective, neuroprotective, and cardioprotective agent due to its well-reported antioxidant, anti-inflammatory, and anti-apoptotic effects (Kannan and Quine 2013; Goswami et al. 2014; Polce et al. 2018, Zhou et al. 2019). Indeed, EA prevented liver damage in several animal models, including, at least, alcohol, carbon tetrachloride (CCL4) cisplatin, cyclosporine, paracetamol, and HFD-induced diabetic rats.

Besides, EA ameliorated hyperlipidaemia and prevented hepatic steatosis in obese, HFD, and transgenic animals with T2DM via several mechanisms, including suppressing SREBP1a and activation of PPARα. EA also suppressed TGs and cholesterol synthesis and accumulation in primary human adipocytes (hASC) and human hepatoma HuH7 cells via stimulating FAs oxidation (Olka et al. 2015). EA can activate AMPK in the adipocytes and muscles (Poulse et al. 2011). Metabolites of EA (i.e., urolithin A, C, and D) prevented TGs synthesis and accumulations in the adipocytes and hepatocytes by activating AMPK and concomitant downregulation of suppressing fatty acid synthase (FAS) (Kang et al. 2016). Furthermore, EA prevented cholesterol (CHOL) synthesis in vivo in cholesterol-fed rats and in vitro by activating AMPK and concomitant suppression of the β-hydroxy ß-methylglutaryl-CoA reductase (HMGCoAR) (Lee et al. 2020).

These data suggest that EA may also act in a similar mechanism in the livers of T1DM-induced rats. Therefore, this study was conducted with two aims. First, to investigate the expression pattern and activity of AMPK in the livers of rats with T1DM induced by streptozotocin; second, to examine if the anti-steatosis effect of EA is mediated by activation of AMPK.

### Materials and methods

#### Animals

Adult male Wistar rats, 130±10 g, 7-weeks-old, were supplied from and maintained in the Experimental Animal Care Centre at King Saud University, Riyadh, Saudi Arabia. The rats were housed in plastic cages (4/cage) in a pathogen-free room and had free access to their diet and drinking water, and were kept under controlled, stable ambient conditions (22 ± 2 oC/12 h light/dark cycle). This study followed the guidelines of Animals in Research: Reporting In Vivo Experiments (ARRIVE) (Kilkenny et al. 2010). All procedures, protocols, treatments, sampling, and euthanasia were approved by the Official Review Board at Princess Nourah University, Riyadh, KSA (IRB Number 20-0096), Riyadh, KSA, which follows the guidelines established by the European Communities Council Directive of 24 November 1986, or the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978) for the care and use of Laboratory Animals for the experimental procedure.

#### DM induction

T1DM was induced in rats using an i.p. single bolus of STZ (65 mg/kg) dissolved in 0.5 M citrate solution (cat Ab142155, Abbac, UK) as described by Wang-Fischer and Garyantes (2018). To prevent death from sudden adverse hypoglycaemia, all rats were orally supplemented with 0.5% glucose. Three days later, plasma glucose levels were measured, and rats with levels higher than 340 mg/dl were considered to have T1DM and included in this study.

#### Experimental design

After the establishment of T1DM in all rats (i.e., 3 d after the initial injection), control and diabetic rats were randomly selected and classified into 5 groups (n = 8/group) and treated directly as the following: 1) control rats (vehicle-treated): were control rats and treated only with an oral dose of 0.1 M NaOH and intraperitoneal (i.p) injected with 0.1% dimethyl sulfoxide (DMSO) (Cat No. 472301, (Sigma Aldrich, St Louis, MO, USA) diluted in phosphate-buffered saline (PBS/pH = 7.4). 2) Control + EA-treated rats: control rats that were orally administered EA (Cat No. E2250, Sigma Aldrich, St Louis, MO, USA) prepared in 0.1 M NaOH, at a final concentration of 50 mg/kg; 3) Control + EA + dorsomorphin (compound C, CC)-treated rats: control rats treated as in group 2 but received a concomitant i.p. dose of CC, an AMPK inhibitor at a final dose of 200 ng/rat/day. 4) T1DM rats: with pre-established T1DM and received a daily oral dose of 0.1 M NaOH and an i.p bolus of 0.1% DMSO as vehicles; 5) T1DM + EA rats: were rats with pre-established T1DM rats and treated orally with EA (50 mg/kg); 6) T1DM + EA + dorsomorphin (compound C, CC)-treated rats: were rats with pre-established T1DM and received a concomitant orally treatment with EA (50 mg/kg) and i.p injected with CC (i.p.) (200 ng/rat/day).

All treatments were given at 10 a.m. every day for 12 weeks on their regimen schedule. Oral treatments were given by gavage using a special stainless steel feeding cannula.

#### Drug preparation and dose selection

As recommended by the supplier and research studies, the solubility of EA is enhanced in alkaline conditions and by dissolving in various concentrations of (0.01, 0.1, and 1 M) NaOH (Rosillo et al. 2011; Zuccari et al. 2020). For this reason, we have prepared EA (10 mg/mL) in 0.1 M NaOH, which showed complete
solubility. This has also been prepared following our previous study (ALTamimi, AlFaris, Aljabryn, et al. 2021). Besides, intragastric administration of EA, dissolved in either 0.1 or 0.1 M NaOH, at this dose demonstrated potent testicular and nephroprotective in T1DM-induced rats (ALTamimi, AlFaris, Aljabryn, et al. 2021; ALTamimi, AlFaris, Alshammari, et al. 2021). A similar dose of EA also prevented hepatic oxidative damage and I/R in rats (Polce et al. 2018). Besides, oral administration of EA at a closer dose of 40 mg/kg protected against DN, lowered serum levels of TGs, CHOL, and LDL, and increased serum HDL levels (Ahad et al. 2014). On the other hand, CC was dissolved in DMSO and diluted to 0.1% in phosphate buffer saline (PBS/pH = 7.4). The in vivo administration, as well as the dose of CC, were adopted from studies by Hasanvand et al. (2016) and Eid et al. (2021), who demonstrated that the rats are tolerable with this dose, which inhibits AMPK in various tissues, including the brain and the heart. This dose has also been confirmed to inhibit AMPK phosphorylation in our preliminary data by more than 78%. Our preliminary data also showed that individual or combined administration of 0.1 M NaOH and/or 0.1% DMSO has no toxicity or systemic side effects (renal, hepatic, cardiac) as compared to control rats which received normal saline, and therefore were used as vehicles the control or model group.

Serum and tissue collection

By the end of week 2, all rats were fasted overnight and anesthetized by 1.9 mg/kg ketamine/xylazine hydrochloride solution. Blood samples were directly collected from the heart using cardiac puncture in plain tubes and centrifuged at 11,000 g for 10 min. All serum samples were collected in new tubes and stored at −20°C for further biochemical analysis. Then, all rats were euthanized using the cervical dislocation protocol. The livers were collected on ice and cut into smaller pieces. Parts of the livers were placed in 10% buffered formalin. Other parts were snap-frozen in liquid nitrogen and stored at −80°C for biochemical and molecular analysis.

Extraction of hepatic lipids from the freshly collected livers

Parts of the freshly collected livers (n = 8/group) were directly used to extract lipid using the methanol: chloroform: normal saline method, as described by Folch et al. (1957). Briefly, parts of the livers 0.25g were homogenized in 10 mL methanol: chloroform solution (1:2 v/v) for 1 h at 4°C. The mixture was filtrated, and 2 mL of normal saline was added to the mixture. The mixture was vortexed and then centrifuged for 10 min at 1200 g. The lower organic layer containing the dissolved lipids was isolated and evaporated. The collected lipids were dissolved in 0.5 mL isopropanol and used for different lipid quantification.

Biochemical analysis

Frozen tissues were homogenized in ice-cold PBS (pH 7.4) and centrifuged at a speed of 11,300 g at 4°C for 15 min to obtain the supernatants. The supernatants were stored at −80°C and used later to measure several biochemical parameters. Serum levels of glucose and insulin were measured using rat colorimetric and ELISA kits (Cat No. 10009582 Cayman Chemical, MI, USA and Ca., No. 589501, Ann Arbor, MI, USA, respectively). Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as hepatic levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH), were measured using rat’ ELISA kits (Cat. No. MBS269614; Cat. No. MBS264975, Cat. No. MBS268427, Cat. No. MBS738685, Cat. No. MBS265966, MyBioSource, CA, USA, respectively). Hepatic levels of ROS were measured using a fluorometric kit (Cat. No. STA-347; Cell Biolabs, CA, USA). Serum and hepatic levels of TGs, HDL, and LDL-c were determined using rats’ specific assay kits (Cat. No. 10010303, Cayman Chemical, MI, Cat. No. K4436, BioVision, CA, USA, and Cat. No. 79960, Crystal Chemicals, USA, respectively). Serum and hepatic levels of FFAs were measured using an assay kit (Cat. No. K612, BioVision, USA). All assays were conducted for 8 samples/group as per the manufacturers’ instructions.

Biochemical measurements in the nuclear fraction

The nuclear fractions of the livers collected from all rats (n = 8 rats/group) were prepared using a special commercial kit (Ab113474, Abcam, Cambridge, UK). The nuclear activities Nrf2 and NF-κB p65 were determined using commercial assay kits (Cat# Ab207223, Abcam, Cambridge, UK, and Cat. No. 40596, Active Motif, Tokyo, Japan, respectively, and per the manufacturers’ instructions.

Quantitative real-time PCR

Primers sequences for the amplification of SREBP1, SREBP2, FAS, β-actin, CPT1a, CPT1b, acetyl Co-A carboxylase (ACC-1), β-hydroxy β-methylglutaryl-CoA reductase (HMGCcAR), and PPARγ were designed and purchased from ThermoFisher and are shown in Table 1. Total RNA was extracted and reversed using the TRizol Reagent (ThromoFisher Scientific, USA) as per the manufacturer’s instructions. First-strand cDNA was synthesised using SuperScript™ VILO™ cDNA Synthesis Kit (Cat. No. 11754050, ThermoFisher Scientific, USA). In brief, 4 μL 5× VILO™ Reaction Mix, 2 μL 10× SuperScript™ Enzyme Mix, 10 μL5 isolated pure RNA (20 ng), and 9 μL DEPC-treated water were placed in each tube and mixed well. The cDNA conditions were: incubation at 25°C for 10 min, heating for 1 h at 42°C, and termination at 85°C for 5 min. qPCR was carried out in 20 μL reaction mixture containing 2 μL cDNA (500 ng/μL), 0.4 μL of 10 μM each primer (200 nm), 10 μL Ssofast Evergreen Supermix, and 7.2 μL of nuclease-free water. qPCR conditions were: inactivation for 1 cycle at 95°C (30 sec); denaturation for 5 sec at 95°C (40 cycles), and annealing at 60°C for 60 sec (40 cycles), and melting for 30 sec at 95°C (1 cycle). Control samples contained no template cDNA. Quantification was done using the ΔΔCT method against 18sRNA as the reference gene. All procedures were conducted according to the manufacturer’s instructions and were done for 8 samples/groups.

Western blotting

Parts of the frozen livers (75 mg) (n = 8 samples/group) were homogenized in 500 μL radioimmunoassay buffer (RIPA) (Cat. No. 89900, ThermoFisher) containing protease inhibitor cocktail (Cat. NO. 78430, ThermoFisher Scientific). The homogenates were centrifuged at a speed of 11,200 g for 10 min at 4°C, and supernatants containing the protein were separated into new tubes. Protein concentrations in all samples were assessed by an assay kit (Cat. No. 5000002, BioRad, TX, USA) and prepared in the loading dye at a final concentration of 2 μg/μL for each
Table 1. Primers used in the PCR reaction.

| Gene        | Primers                                      | GenBank accession # | Product length |
|-------------|----------------------------------------------|---------------------|---------------|
| SREBP-1c    | F5'-GCA AGG CCA TCG ACT ACA TC-3'            | NM_001276707.1      | 161           |
|             | R5'-TTT CAT GCC CTC CAT AGA CAC-3'           |                     |               |
| HMG-CoAR    | F5'-TGTTCAGGGGCTGCAAGACACA-3'                | NM_013134           | 202           |
|             | R5'-TCGAAGCCTCTTCTGTGACGAT-3'                |                     |               |
| PPAR-γ      | F5'-TCCGAGCTACAGTACTTACGG-3'                 | NM_013196.1         | 116           |
|             | R5'-CTTGGAGAGGTGGTTGCTGT-3'                  |                     |               |
| SREBP-2     | F5'-CTGACCAATGCTGGTTAAT-3'                   | NM_01033694.1       | 204           |
|             | R5'-CTTGGTACATGGTTGGTCTG-3'                  |                     |               |
| FAS         | F5'-GCC ATT TCC ATT GCC CTT AGC-3'           | NM_017332           | 273           |
|             | R5'-CTG AGC CAA GCA CCA GCA CAC ACT-3'       |                     |               |
| CPT1a       | F5'-TCCGGAGGAGGCCCCATC-3'                    | NM_013200.1         | 142           |
|             | R5'-TTCGCTGTCAGCTTGCCTGG-3'                  |                     |               |
| ACC-1α      | F5'-GCT GAA GTG AAC AAT CCC TT-3'            | NM_017075.2         | 200           |
|             | R5'-GAG CCA TGC CTC TAG TAC CT-3'            |                     |               |
| β-actin     | F5'-ATC TGG CAC ACC TTC ACC-3'               | NM_031144           | 291           |
|             | R5'-AGC CAG GTC CAG ACG CA-3'                |                     |               |

Table 2. Alteration in final body weights, food intake, liver weights, and fasting plasma and levels glucose in all experimental groups.

| Parameter                  | Control | Control + EA | Control + CC | T1DM | T2DM + EA | T1DM + EA + CC |
|----------------------------|---------|--------------|--------------|------|----------|----------------|
| Plasma                     |         |              |              |      |          |                |
| Final body weight (g)      | 412 ± 46| 429 ± 31     | 444 ± 29     | 339 ± 41 ^abc | 409 ± 23 ^d | 319 ± 29 ^abce |
| Liver weights (g)          | 15.6 ± 2.8 | 15.9 ± 2.2  | 14.3 ± 2.5   | 21.8 ± 3.1 ^abc | 16.5 ± 2.9 ^d | 19.9 ± 3.3 ^abce |
| Weekly food intake (g/6 rats) | 1212 ± 100 | 1190 ± 119  | 1231 ± 87   | 1876 ± 147 ^abc | 1321 ± 189 ^abce | 1992 ± 214 ^abce |
| Fasting glucose (mg/dl)    | 103 ± 7.8 | 86 ± 6.9    | 112 ± 6.4 ^a | 328 ± 22.4 ^abc | 181 ± 14.5 ^abce | 356 ± 33.1 ^abce |
| Fasting insulin (U/l)      | 4.6 ± 0.53 | 4.1 ± 0.67  | 4.7 ± 0.71   | 1.4 ± 0.25 ^abc | 2.7 ± 0.61 ^abcd | 1.1 ± 0.31 ^abc |
| Serum                      |         |              |              |      |          |                |
| ALT (U/l)                  | 41 ± 7.8 | 45 ± 8.1     | 41 ± 5.9     | 113 ± 11.7 ^abc | 56 ± 5.6 ^abcd | 109 ± 8.5 ^abc |
| AST (U/l)                  | 23.4 ± 4.7 | 25.7 ± 6.1  | 21.5 ± 6.3   | 93.5 ± 8.4 ^abc | 37.1 ± 6.2 ^abcd | 93.2 ± 7.1 ^abcd |

Data are presented as the mean ± SD for n = 8 rats/group. Significance was determined at p < 0.05. ^abc: significantly different as compared to control; ^abce: significantly different as compared to control + Ellagic acid (EA); ^: significantly different as compared to control + EA + compound C (CC, and AMPK inhibitor); ^: significantly different as compared to T1DM-induced rats; and ^: significantly different as compared to T1DM + EA-treated rats.

Statistical analysis

Statistical analyses for all measured parameters were processed using Graph Pad Prism statistical software package (version 6). Data were analyzed using the 1-way ANOVA followed by Tukey’s t-test as a post hoc test. Data were considered significantly different at p < 0.05 and were presented as means pulse/minus standard deviation (mean ± SD).

Results

**EA exerts a hypoglycaemic, hypolipidemic, and insulin-releasing effect in an AMPK-dependent manner**

Administration of EA to control alone or in conjugation with CC, an AMPK inhibitor, didn’t significantly alter food intake, final body weights, liver weights, nor fasting insulin levels as compared to control rats (Table 2). However, administration of EA to control rats significantly reduced fasting serum insulin, TGs, CHOL, LDL-c, and FFAs levels, as well as hepatic levels of TGs, CHOL, and FFAs as compared to control rats (Tables 2 and 3). No significant alterations in the levels of serum glucose, TGs, CHOL, LDL-c, and FFAs, as well as in the hepatic levels of CHOL, TGs, and FFAs were seen when control + EA + CC-treated rats were compared with the control rats (Tables 2 and 3). Nonetheless, T1DM-induced rats showed a significant

**Light microscope**

Freshly collected livers were placed in 10% buffered formalin. After 24 h, all samples were dehydrated in ascending alcohol concentrations (70–100%). All tissues were then cleared in xylene, embedded in paraffin, and cut by the microtome at a thickness of 3 μm. Then, all the slides were routinely stained with haematoxylin and eosin (H&E) or Masson trichrome stain (for fibrosis) and examined under a light microscope by a pathologist who is unaware of the experimental groups. For each slide, 5 fields from different areas were captured.

Sample. All samples were then boiled for 5 min and separated by the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at a final concentration of 40 μg/well. All gels were then transferred on nitrocellulose membranes, washed, and blocked by 5% of skimmed milk for 1 h. Then the membranes were washed again and incubated with the mouse monoclonal antibodies primary antibodies against AMPK (Cat. No. 2532), p-AMPK (Thr 172) (Cat. No. 50081), or β-actin (Cat. No. 3700) (Cell Signalling Technology) for 2 h at room temperature with rotation. Then the membranes were washed again and blotted with the secondary horse radish-peroxidase (HRP)-conjugated antibody for another 2 h at room temperature. All washing between the steps was done 3 times each of 10 min with 1× Tris-buffered saline-Tween 20 (TBST) buffer. Antibodies were prepared in the TBST buffer. Bands of the interactions between the primary and 2nd antibodies on each blot were developed using a 5 min incubation with ECL pierce kit substrate reagents (Cat. No. 32109, ThermoFisher) and were scanned and photographed using the C-Di Git blot scanned and associated software (LI-COR, USA). Expression of both AMPK and p-AMPK were expressed relative to the expression of β-actin.

Statistical analyses for all measured parameters were processed using Graph Pad Prism statistical software package (version 6). Data were analyzed using the 1-way ANOVA followed by Tukey’s t-test as a post hoc test. Data were considered significantly different at p < 0.05 and were presented as means pulse/minus standard deviation (mean ± SD).
reduction in final body and fasting insulin levels with a concomitant increase in the weekly food intake, liver weights, and fasting glucose levels (Table 2). They also showed a significant increase in the serum and hepatic levels TGs, CHOL, and FFAs, as well as in serum LDL levels as compared to control rats (Table 3). All these events were significantly reversed in T1DM \( + \) EA as compared to T1DM-induced rats and were prevented by co-admixture of CC (Tables 2 and 3). Except for final body weights, food intake, and liver weights, the levels of all the serum and hepatic endpoints were slightly but significantly higher in T1DM \( + \) EA-treated rats as compared to control rats (Tables 2 and 3). However, the levels of all these parameters were not significantly different when T1DM \( + \) EA \( + \) CC-treated rats were compared with T1DM-induced rats (Tables 2 and 3).

**EA prevents hepatic lipid accumulation at the histological levels in an AMPK-dependent manner**

Livers from control, control \( + \) EA, and control \( + \) EA \( + \) CC-treated rats showed normal histological structures with intact sinusoids and normally appeared hepatocytes radiating from the central vein (Figure 1(A–C)). However, dilated central vein with increased lipid droplets accumulation of all sizes with a parallel increase in inflammatory cells around the portal vein was observed in the T1DM-induced rats (Figures 1(D) and 2(A)). On the other hand, much improvement with almost normal liver structure and very few fat vacuolizations in a limited number of cells were observed in T1DM \( + \) EA-treated rats (Figure 2(B)). Similar morphological alterations with increased lipid droplet accumulation and increased inflammatory cell infiltration around the congestive portal vein were observed in T1DM \( + \) EA \( + \) CC-treated rats (Figure 2(C,D)).

**EA, in an AMPK-dependent manner, suppresses oxidative stress and inflammation by inhibiting NF-\(\kappa\)B p65 and activating Nrf2**

Levels of ROS, MDA, TNF-\(\alpha\), IL-6, as well as the nuclear activity of NF-\(\kappa\)B p65, were significantly increased but the nuclear activity of Nrf2 was significantly decreased in the liver of T1DM-induced rats as compared to control rats (Figures 3(A–D) and 4 (A–D)). However, hepatic levels of TNF\(\alpha\) and IL-6, levels of

---

**Table 3. Changes in liver weight and serum and hepatic fractions in all groups of rats.**

| Parameter | STD | Control \(+\) EA | Control \(+\) EA \(+\) CC | T1DM | T2DM \(+\) EA | T1DM \(+\) EA \(+\) CC |
|-----------|-----|------------------|---------------------------|------|--------------|-------------------------|
| Serum     |     |                  |                           |      |               |                         |
| TGs (mg/dl) | 46.2 ± 6.7 | 35.2 ± 4.1*      | 49.8 ± 7.1*               | 121.1 ± 9.8*abc | 61.4 ± 6.3abcd | 129 ± 8.1*abcce         |
| CHOL (mg/dl) | 78.3 ± 7.8 | 61.2 ± 7.1*      | 83.5 ± 9.1*               | 173 ± 15.4*abc | 73.4 ± 9.2bcd | 181 ± 13.9*abc         |
| LDL-c (mg/dl) | 36.5 ± 5.6 | 22.6 ± 4.7*      | 40.3 ± 7.5*               | 83.5 ± 7.4*abc | 43.5 ± 6.9*abc | 88.3 ± 8.5*abcde       |
| FFAs (\(\mu\)mol/l) | 135 ± 15.4 | 110 ± 13.4*      | 143 ± 17.4*               | 372 ± 24.5*abc | 222 ± 12.6*abc | 355 ± 31.3*abcde       |

Liver

| Parameter | Std | Control \(+\) EA | Control \(+\) EA \(+\) CC | T1DM | T2DM \(+\) EA | T1DM \(+\) EA \(+\) CC |
|-----------|-----|------------------|---------------------------|------|--------------|-------------------------|
| Triglycerides (\(\mu\)g/g) | 724 ± 88.9 | 609 ± 48.4*      | 812 ± 73.4*               | 3823 ± 413*abc | 1092 ± 112*abc | 3293 ± 318*abcde       |
| CHOL (\(\mu\)g/g) | 218 ± 18.6 | 178 ± 14.4*      | 231 ± 22.1*               | 518 ± 49.2*abc | 265 ± 34.2*abc | 539 ± 41.5*abcde       |
| FFA (\(\mu\)mol/g) | 43.2 ± 6.8 | 33.2 ± 4.4*      | 49.3 ± 7.3*               | 132 ± 18.4*abc | 83.3 ± 8.8*abc | 147 ± 15.6*abcde       |

Data are presented as the mean ± SD for \(n = 8\) rats/group. Significance was determined at \(p < 0.05\). *: significantly different as compared to control; \(\ast\): significantly different as compared to control \(+\)Ellagic acid (EA); \(\ast\): significantly different as compared to control \(+\) EA \(+\) compound C (CC, and AMKP inhibitor); \(\ast\): significantly different as compared to T1DM-induced rats; and \(\ast\): significantly different as compared to T1DM \(+\) EA-treated rats.
Figure 2. Histological sections from some experimental groups of rats as stained by haematoxylin and eosin (H &E). A was taken for T1DM-induced rats and showed severe congestion in the portal vein (PV) that is surrounded by increased infiltration of inflammatory cells (curved arrow). B was taken from a T1DM + EA-treated rat and showed almost normal architectures like those seen in the control rats with normal hepatocytes (long arrow). However, very few cytoplasmic lipid accumulations are still seen in few hepatocytes. C and D were taken from T1DM + EA + CC and showed similar abnormal features like those observed in T1DM-induced rats including increased accumulation of large, medium, and small cytoplasmic lipid droplets (long arrow, short arrow, and arrowheads, respectively), with increased accumulation of inflammatory cells around the congestive portal vein (PV) (curved arrow).

Figure 3. Levels of oxidative stress markers in the livers of all groups of rats. Data are presented as the mean ± SD for n = 8 rats/group. Significance was determined at p < 0.05. a: significantly different as compared to control; b: significantly different as compared to control + ellagic acid (EA); c: significantly different as compared to control + EA + compound C (CC, and AMKP inhibitor); d: significantly different as compared to T1DM-induced rats; and e: significantly different as compared to T1DM + EA-treated rats.
ROS, MDA, and nuclear levels of NF-κB p65 were significantly decreased and the nuclear levels of Nrf-2 were significantly increased in the levels of both control + EA and T1DM + EA-treated rats as compared either to the control or T1DM-induced rats, respectively (Figures 3(A–D) and 4(A–D)). Also, hepatic levels of TNF and IL-6 were not significantly different between the control and control + EA-treated rats but were significantly decreased in the livers of T1DM + EA-treated rats as compared to T1DM-induced rats (Figure 4(A,B)). No significant variation in the levels of all these markers was seen when control + EA + CC were compared to control rats or when T1DM + EA + CC were compared with control or T1DM-induced rats (Figures 3(A–D) and 4(A–D)).

EA suppresses hepatic lipogenesis by suppressing SREBP1/2 and activating the PPARα/CPT1, in an AMPK-dependent manner

mRNA levels of SREBP1, SREBP2, FAS, HMGCoAR were significantly increased but mRNA levels of PPARα, CPT1a, and CPT1b were significantly decreased in the livers of T1DM-induced rats as compared to control rats (Figure 6(A–C)). mRNA levels of SREBP1, SREBP2, FAS, HMGCoAR were significantly decreased but mRNA levels of PPARα, CPT1a, and CPT1b were significantly increased in the livers of both control + EA and T1DM-treated rats as compared to either the control rats or T1DM-induced rats, respectively (Figure 6(A–C)). mRNA levels of all these proteins were not significantly different between T1DM + EA-treated rats as compared to control rats (Figure 5(A)). However, administration of CC to both the control + EA or T1DM + EA significantly increased mRNA levels SREBP1, SREBP2, FAS, HMGCoAR and decreased mRNA levels of PPARα, CPT1a, and CPT1b as compared to either the control + EA-treated rats or T1DM + EA-treated rats, respectively (Figure 6(A–C)). No significant variation in mRNA levels of all these genes was seen when a comparison was made between the control and control + EA + CC or between T1DM + EA + CC and T1DM-induced rats (Figure 6(A–C)).

Discussion

The findings of this study show that chronic administration of EA ameliorates hepatic damage and steatosis in STZ-induced
T1DM in rats, mainly by its hypoglycaemic and antioxidant effects and activating AMPK. Suppression of AMPK by CC abolished all these beneficial health benefits of EA effects. A summary of these findings is summarized in Figure 7.

T1DM is characterized by sustained hyperglycaemia, hypoinsulinemia. Polyphagia and weight loss is a common feature of T1DM due to increased muscle wasting and peripheral lipolysis in response to the severe reduction in insulin levels (Enoksson...
et al. 2003). We have validated our animal model by the obvious increase in fasting glucose and insulin levels, as well as the higher food intake and the significant reduction in rats’ body weights by the end of the study. Besides, T1DM-induced rats had significantly higher serum and hepatic levels of FFAs, which confirmed a higher peripheral lipolysis rate. All these effects were ameliorated by the co-administration of EA, thus suggesting potent hypoglycaemic and antidiabetic properties of EA against T1DM. In particular, EA lowered fasting blood glucose levels in both control and STZ-diabetic rats but stimulated insulin levels and restored normal body weights in the STZ-diabetic rats. In the same line, the hypoglycaemic and insulin lowering potential of EA was found in rodents with T1DM and T2DM and was mediated by several mechanisms including hepatic stimulating β-survival, and ameliorating peripheral insulin resistance (Fatima et al. 2017; Nankar and Doble 2017; Polce et al. 2018; Farbood et al. 2019). However, our data extend these findings and add a possible mechanism linking all these effects together.

Accordingly, we have found that the hypoglycaemic but not the insulin stimulatory effect of EA is AMPK-dependent. Activities of AMPK were significantly reduced in the livers of STZ-diabetic rats of this study and were significantly increased by the administration of EA. Supporting our data, AMPK levels were significantly reduced in rodents with NAFLD (Fogarty and Hardie 2010; Lindholm et al. 2013; Smith et al. 2016; Liou et al. 2019; Zhang et al. 2019). However, we have found that the concurrent administration of CC along with EA abolished its hypoglycaemic effect. Indeed, AMPK can lower fasting blood glucose levels by suppressing hepatic gluconeogenesis, improving hepatic and peripheral insulin sensitivity, and stimulate GLUT-4 expression on the muscle cells (Viollet et al. 2009; Ruderman et al. 2013). Also, EA and its metabolites urolithin A, C, and D, stimulated AMPK activity in primary adipocytes, hepatoma Huh7 cells, and livers of high-CHOL-fed rats (Poulose et al. 2011; Kang et al. 2016; Lee et al. 2020).

On the other hand, hyperglycaemia stimulates the generation of ROS in the livers of diabetic rats by increasing influx of FFAs and inflammatory cytokines from the impaired adipose tissue, damaging the mitochondria, and activation of several ROS-generating pathways (Ghosh et al. 2015; Mohamed et al. 2016; Lee et al. 2017). In diabetic rats of both types, ROS not only irreversibly induces oxidative modification to protein, lipids, and DNA, but also increase the infiltration of leukocytes, activate inflammation by regulating NF-kB, and induces cell apoptosis mainly by activating the intrinsic (mitochondria-mediated) cell death (Panasiuk et al. 2006; Baffy 2009; Francês et al. 2010; Palsamy et al. 2010; Romagnoli et al. 2010; Leung and Nieto 2013; Ghosh et al. 2015; Rodriguez et al. 2018; Kawai et al. 2020; Lee et al. 2020). However, levels of Nrf2 and its downstream cellular antioxidants, including GSH and other antioxidant enzymes, are significantly depleted under hyperglycaemic conditions and participate significantly in T1DM-induced liver damage (Ahmed 2005; Han et al. 2006; Parveen et al. 2010; Elango et al. 2016).

Higher levels of ROS and MDA (a marker of lipid peroxidation), reduced levels of GSH and SOD, increased nuclear activation of NF-κB p65, higher levels of TNF-α, and IL-6 were
observed in the livers of STD-diabetic rats. However, EA was able to reverse all these events in the livers of diabetic rats. Although these events could be explained by ameliorating hyperglycaemia and improving insulin levels, EA also reduced levels of ROS and MDA and the nuclear activation of NF-κB and stimulated the nuclear activity and levels of GSH and SOD in the livers of control rats. These data suggest potent antioxidant, anti-inflammatory, and anti-apoptotic effects of EA, possibly through the transactivation of Nrf2.

Supporting these data, the hepatic protective effect of EA has been also confirmed in alcohol, ConA, Hg, CCl₄, paracetamol, cisplatin, rifampicin, CsA, and D-Gal/LPS-induced liver damage where the protection was mediated by inhibiting ROS generation and activating Nrf2/antioxidants axis (reviewed in García-Niño and Zazueta (2015). In this review, the unique structure of EA, which contains four hydroxyls and two lactone functional groups, can scavenge different types of free radicals (Gozzi et al. 1995; Nugroho et al. 2014). EA prevented liver, kidney, lung, and keratinocyte damage and apoptosis by activating Nrf2 and stimulating GSH and antioxidant enzymes (Barch and Rundhaugen 1994; Shepherd et al. 2000; Hseu et al. 2012; Celik et al. 2013; Kim et al. 2013; Gu et al. 2014; Vijaya Padma et al. 2014). Also, EA inhibited NF-κB in the renal tissues of T1DM (Ahad et al. 2014). In the same way, EA protected the mice against sleep deprivation-induced memory loss by suppressing TLR-4/NF-κB and activating Nrf2 (Wang et al. 2021). EA prevents hepatic fibrosis in several animal models by downregulating TGF-β1 expression and activating several fibronectin molecules such as matrix metalloproteinases-2/9 (MMP-2 and MMP-9) (Devipriya et al. 2007; Suzuki et al. 2009).

Another interesting observation noticed in this study is that the effects of EA on the activities of both NR12 and NF-κB in the livers of both the control and STZ-diabetic rats were largely abolished by suppressing AMPK with CC, thus confirming that the antioxidant and anti-inflammatory effects of EA are AMPK dependent. Indeed, several lines of evidence have shown that AMPK can decrease oxidative stress and inflammation in various stress conditions by downregulating the transcription of NF-κB, suppressing NF-κB signalling and inflammatory cytokines synthesis, and stimulating Nrf2 expression and nuclear activation (Peairs et al. 2009; Salminen et al. 2011; Wang et al. 2012; Sid et al. 2013; Mo et al. 2014; Zimmermann et al. 2015; Xu et al. 2018; Xiang et al. 2019).

NAFLD is a common feature observed in both T1DM and T2DM (Bhatt and Smith 2015; Hazlehurst et al. 2016). The disease is characterized by several biochemical and histological alterations due to different mechanisms including hyperglycaemia, increase the influx of FFAs from adipose tissue, hepatic I/R, and oxidative damage (Mohamed et al. 2016; Sviklåne et al. 2018; Tripolino et al. 2019). The initial stage of the disease includes an accumulation of fat vacuoles in the cytoplasm of the hepatocytes (microvascular steatosis) which progressive in the later stages to macrovesicular steatosis, where the lipid vacuole reside in the nuclei (Tripolino et al. 2019). In the presence of increased inflammatory cell infiltrates and pericellular, perisinusoidal, and periportal fibrosis, NAFLD can develop to steatohepatitis (Tripolino et al. 2019). These conditions are associated with dyslipidemia and significant increment in the circulatory levels of liver injury-related enzymes. Similar observations were also seen in the livers of STZ-induced rats of this study, thus confirming previously reported studies that T1DM in both humans and experimental animals are associated with NAFLD and dyslipidemia (Hazlehurst et al. 2016; Mohamed et al. 2016; Sviklåne et al. 2018; Tripolino et al. 2019; de Vries et al. 2020). However, the ability of EA to reduce hepatic lipid accumulation, ameliorate the resulted dyslipidemia, and the increment in the levels of ALT and AST with the previously discussed ameliorative effect on liver fibrosis was the clearest evidence that EA could prevent NAFLD in T1DM-induced rats.

Stimulated lipogenesis mediated by overexpressing SREBP1 and SREBP2 and their target genes (i.e., FAS/ACC-1 and HMGCoAR) with a concomitant reduction in β-oxidation due to suppression of PPARα/CPT1 axis mediated NAFLD in diabetic animals (Oliveira et al. 2012) and were shown in this study. On the contrary, chronic administration of EA suppressed the transcription of SREBP1, SREBP2, FAS, ACC-1, and HMGCoAR and significantly upregulated levels of PPARα and CPT1a, and CPT1b not in only in the livers of T1DM-induced rats but also in the livers of control rats. Although these data are being unique to be shown in the T1DM-induced rats of this study, many previous studies have shown a protective effect of EA against NAFLD in rodents with T2DM (Yoshimura et al. 2013; García-Niño and Zazueta 2015; Okla et al. 2015; Kang et al. 2016; Zhang et al. 2019; Lee et al. 2020).

The current study demonstrates that EA also ameliorates hepatic steatosis by activating AMPK. This was confirmed later where CC prevented the anti-steatotic effect of EA and its impact on these transcription factors in the livers of both the control and STZ-diabetic rats. Indeed, AMPK is a novel molecule that can treat NAFLD and NASH by inhibiting lipogenesis through suppressing SREBP1/2 and upregulating PPARα (Strzyz 2020; Tian et al. 2020). Therefore, we could strongly suggest that EA prevents hepatic steatosis in STZ-induced T1DM in rats by activating hepatic AMPK.

Conclusions
The data reported in this study confirm the ability of EA to treat NAFLD in diabetic animals and show a possible mechanism of action. Therefore, these data encourage further subclinical and clinical trials, which could provide a novel therapy to alleviate the complication associated with this disorder in affected individuals.

Acknowledgements
The authors would like to thank the technical staff of the animal house at King Saud University for their help in taking care of the animals during the whole period of the experimental study.

Ethical statement
All experiments conducted in this study have been approved by the official Review Board at Princess Nourah University, Riyadh, KSA (IRB Number: 20-0096).

Author contributions
Conceptualization: JZA, GMA, and NAA; Methodology: RIA, DHA, and HA; Biochemical analysis: MAA, NAA, and MAY; Original Draft Writing & Editing: All authors.
Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, through the Research Groups Program under Grant: [RGP-1441 – 0032].

ORCID
Jozaa Z. ALTamimi http://orcid.org/0000-0002-5510-0768
Ghedeir M. Alshammari http://orcid.org/0000-0002-2043-1209
Nora A. ALFaris http://orcid.org/0000-0002-9135-5725
Reham I. Alagal http://orcid.org/0000-0002-8515-1574
Dalal H. Aljabryn http://orcid.org/0000-0002-4125-1303
Mohammed Abdo Yahya http://orcid.org/0000-0002-5665-9600

References
Ahad A, Ganai AA, Mjeeb M, Siddiqui WA. 2014. Ellagic acid, an NF-kB inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chem Biol Interact. 219:64–75.
Ahmed N. 2005. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 67(1):3–21.
ALTamimi JZ, ALFaris NA, Aljabryn DH, Alagal RI, Alshammari GM, Aldera A, Alqhtani S, Yahya MA. 2021. Ellagic acid improved diabetes mellitus-induced testicular damage and sperm abnormalities by activation of Nrf2. Saudi J Biol Sci. 11.
ALTamimi JZ, ALFaris NA, Alshammari GM, Aldera A, Aljabryn DH, Aldera A, Alqhtani S, Yahya MA. 2021. Ellagic acid protects against diabetic nephropathy in rats by regulating the transcription and activity of Nrf2. J Funct Foods. 79:104397.
Araujo AR, Rosso N, Bedogni G, Tirielli C, Bellentani S. 2018. Global epidemiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: what we need in the future. Liver Int. 38:47–51.
Aslan A, Gok O, Beyaz S, Agca CA, Erman O, Zerek A. 2020. Ellagic acid prevents kidney injury and oxidative damage via regulation of Nrf-2/NF-κB signaling in carbon tetrachloride induced rats. Mol Biol Rep. 47(10):7959–7970.
Ahyanci A, Cengiz M, Mehtap Kutlu H, Vejselova D. 2016. Protective effects of ellagic acid in β-galactosamine-induced kidney damage in rats. Cytochemistry. 68(5):1763–1770.
Baffy DH, Rundhaugen LM. 1994. Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis. 15(9):2065–2068.
Bhatt HB, Smith RJ. 2015. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 4(2):101–108.
Celik G, Semir A, Karakurt S, Arslan S, Adali O, Sen A. 2013. A comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat. Biomed Res Int. 2013:358945.
Cozzi R, Ricordy R, Bartolini F, Ramadori L, Perticone P, De Salvia R. 1995. Taurine and ellagic acid: two differently-acting natural antioxidants. Environ Mol Mutagen. 26(3):248–254.
de Souza CO, Texeira AAS, Biondo LA, Lima Junior EA, Ratatinha HAP, Rosa Neto JC. 2017. Palmitoleic acid improves metabolic functions in fatty liver by PPARα-dependent AMPK activation. J Cell Physiol. 232(8):2168–2177.
Devipriya N, Sudheer AR, Srinivasan M, Menon VP. 2007. Effect of ellagic acid, a plant polyphenol, on fibrotic markers (MMPs and TIMPs) during alcohol-induced hepatotoxicity. Toxicol Mech Methods. 17(6):349–356.
de Vries M, Westerink J, Kaasager KH, de Valk HW. 2020. prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab. 105(12):3842–3853.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLOS Biol. 8(6):e1000412.

Kim YS, Zerin T, Song YH. 2013. Antioxidant action of eplagic acid ameliorates paraglutamine-induced A549 cytotoxicity. Biol Pharm Bull. 36(4):609–615.

Kitade H, Chen G, Ni Y, Ota T. 2017. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 9(4):387.

Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitze U, Muller-Wieland D, Kotzka J. 2012. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLOS One. 7(2)e31812.

Kulkarni SR, Xu J, Donepudi AC, Wei W, Slitt AL. 2013. Effect of caloric restriction and AMPK activation on hepatic nuclear receptor, biotransformation enzyme, and transporter expression in lean and obese mice. Pharm Res. 30(9):2232–2247.

Lee KH, Jeong ES, Jang G, Na JR, Park S, Kang WS, Kim E, Choi H, Kim JS, Kim S. 2020. Unripe Rubus coreanus miquel extract containing ellagic acid regulates AMPK, SREBP-2, HMGCR, and INSIG-1 signaling and cholesterol metabolism in vitro and in vivo. Nutrients. 12(3):610.

Lee JY, Kim MY, Shin SH, Lim MR, Kwon OJ, Kim TH, Park CH, Noh JS, Rhee MH, Roh SS. 2017. Persicaria isolated from Oenothera javanica protects against diabetes-induced oxidative stress and inflammation in the liver of streptozotocin-induced type I diabetic mice. Exp Ther Med. 13(4):1940–1942.

Leung TM, Nieto N. 2013. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 58(2):395–398.

Lindholm CR, Ertel RL, Bauwens JD, Schmuck EG, Mulligan JD, Saupe KW. 2010. Protective effect of ellagic acid alleviates hepatic oxidative stress and inflammation in the liver of streptozotocin-induced type I diabetic rats. Free Radic Biol Med. 49(2):171–177.

Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA. 2011. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn’s disease. Biochem Pharmacol. 82(7):737–745.

Ruderman NB, Carling D, Pretinki M, Caccimedes J. 2013. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 123(7):2764–2772.

Salminen A, Hyytinne JM, Kaarniranta K. 2011. AMP-activated protein kinase inhibits NF-kB signaling and inflammation: impact on healthspan and lifespan. J Mol Med. 89(7):667–676.

Seo CS, Jeong SJ, Yoo SR, Lee NR, Shin HK. 2016. Quantitative analysis and in vitro anti-inflammatory effects of gallic acid, ellagic acid, and quercetin from radix sanguisorbae. Pharmacogn Mag. 12(46):104–108.

Shepherd AG, Manson MM, Ball HW, McLellan LL. 2000. Regulation of rat glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) subunits by chemo preventive agents and in aflatoxin B(1)-induced preneoplasia. Carcinogenesis. 21(10):1827–1834.

Sib B, Vernez J, Calderon PB. 2013. Role of AMPK activation in oxidative cell damage: implications for alcohol-induced liver disease. Biochem Pharmacol. 86(2):200–209.

Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. 2016. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 311(4):E730–E740.

Strazzy P. 2020. AMPK against NASH. Nat Rev Mol Cell Biol. 21(4):181.

Suzuki N, Masamune A, Kikutai K, Watanabe T, Satoh K, Shimosegawa T. 2009. Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig Dis Sci. 54(4):802–810.

Svihline L, Olmene E, Dzerve Z, Kupcs K, Pirags V, Sokolovskaja J. 2018. Fatty liver index and hepatitis steatosis index for prediction of nonalcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 33(1):270–276.

Tian X, Qu X, Qiong Q, Wen Z, Chen Y. 2020. Catalpol attenuates hepatic steatosis by regulating lipid metabolism via AMP-activated protein kinase activation. Biomed Res Int. 2020:6708061.

Tomita K, Tamiya G, Ando S, Kitamura N, Koizumi H, Kato S, Hori Y, Kaneko T, Azuma T, Nagata H, et al. 2005. AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcohol Clin Exp Res. 29(12 Suppl):245S–248S.

Ucar F, Sezer S, Erdogan S, Armutcu F, Akyol O. 2013. The role of AMPK activation in oxidative stress and nonalcoholic fatty liver disease via promotion of the Sirt-1/AMPK pathway in mice fed a high-fat diet. Cells. 8(5):447.

Vijaya Padma V, Kalai Selvi P, Srvanni S. 2014. Protective effect of ellagic acid against type 2 diabetes complications. Diabetes Metab Syndr Obes. 7:210–216.

Wang N, Ma H, Li J, Meng C, Zou J, Wang H, Liu K, Liu M, Xiao Z, Zhang H, et al. 2021. HSF1 functions as a key defender against palmitic acid-induced ferroptosis in cardiomyocytes. J Mol Cell Cardiol. 150:65–76.
